Trial · NCT03112174
Participant flow25
How many started, completed or left each group, period by period.
1 to 20 of 25
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Safety Run-in: Increased TLS Risk at Baseline | 15 | |
| Overall Study | STARTED | Safety Run-in: Low TLS Risk at Baseline | 6 | |
| Overall Study | STARTED | Randomization Phase: Ibrutinb + Venetoclax | 134 | |
| Overall Study | STARTED | Randomization Phase: Ibrutinib + Placebo | 133 | |
| Overall Study | STARTED | Treatment-naive Open-label Arm | 78 | |
| Overall Study | On Study Treatment at Study Closure | Safety Run-in: Increased TLS Risk at Baseline | 0 | |
| Overall Study | On Study Treatment at Study Closure | Safety Run-in: Low TLS Risk at Baseline | 2 | |
| Overall Study | On Study Treatment at Study Closure | Randomization Phase: Ibrutinb + Venetoclax | 31 | |
| Overall Study | On Study Treatment at Study Closure | Randomization Phase: Ibrutinib + Placebo | 21 | |
| Overall Study | On Study Treatment at Study Closure | Treatment-naive Open-label Arm | 26 | |
| Overall Study | Off Treatment and On Study Follow Up at Study Closure | Safety Run-in: Increased TLS Risk at Baseline | 2 | |
| Overall Study | Off Treatment and On Study Follow Up at Study Closure | Safety Run-in: Low TLS Risk at Baseline | 0 | |
| Overall Study | Off Treatment and On Study Follow Up at Study Closure | Randomization Phase: Ibrutinb + Venetoclax | 22 | |
| Overall Study | Off Treatment and On Study Follow Up at Study Closure | Randomization Phase: Ibrutinib + Placebo | 25 | |
| Overall Study | Off Treatment and On Study Follow Up at Study Closure | Treatment-naive Open-label Arm | 25 | |
| Overall Study | COMPLETED | Safety Run-in: Increased TLS Risk at Baseline | 2 | |
| Overall Study | COMPLETED | Safety Run-in: Low TLS Risk at Baseline | 2 | |
| Overall Study | COMPLETED | Randomization Phase: Ibrutinb + Venetoclax | 53 | |
| Overall Study | COMPLETED | Randomization Phase: Ibrutinib + Placebo | 46 | |
| Overall Study | COMPLETED | Treatment-naive Open-label Arm | 51 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03112174/flow